Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 121Neoplasms, Plasma Cell 36Recurrence 7Immunoglobulin Light-chain Amyloidosis 5Renal Insufficiency 2Neoplasms 2Amyloidosis 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Sarcoma 1Salivary Gland Neoplasms 1Renal Insufficiency, Chronic 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polyneuropathies 1Plasmacytoma 1Pinealoma 1Pathologic Complete Response 1Paraproteinemias 1Pancreatic Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neurotoxicity Syndromes 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1

Interventions

Dexamethasone 6Lenalidomide 4Cyclophosphamide 4Melphalan 3daratumumab 2carfilzomib 2Prednisone 2ricolinostat 1pomalidomide 1deltacortene 1Transplantation, Autologous 1Thalidomide 1Calcium Dobesilate 1Bortezomib 1Bone Marrow Examination 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease × Thalidomide × Plasma cell × Clear all
NCT00232934 2018-08-02

Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients

Gruppo Italiano per lo Studio del Mieloma Multiplo

Phase 3 Completed
400 enrolled
Plasma cell

Disease, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡